课题基金 / 基金详情

PHARMACOKINETICS OF RIBAVIRIN IN SUBJECTS WITH CHRONIC LIVER DISEASE

PHARMACOKINETICS OF RIBAVIRIN IN SUBJECTS WITH CHRONIC LIVER DISEASE
利巴韦林在慢性肝病患者中的药代动力学
批准号：
6120071
负责人：
STEVEN SCHENKER
金额：
$1.64万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6120071
关键词：
chronic disease /disorder clinical research clinical trial phase I combination chemotherapy dosage drug screening /evaluation hepatitis C human subject human therapy evaluation immunotherapy interferons liver disorder chemotherapy microorganism disease chemotherapy pharmacokinetics ribavirin

项目摘要

项目成果

STEVEN SCHENKER的其他基金

相似基金

相关文献

中文摘要
翻译
用干扰素治疗慢性病毒性肝炎只有20%左右的患者有效。利巴韦林还可以降低慢性丙型肝炎患者的异常肝脏检查。希望干扰素和利巴韦林的联合治疗将提高单独药物的治疗潜力。这项研究将比较单剂利巴韦林在对照组和不同严重程度的肝病患者中的消除情况，从而评估慢性丙型肝炎患者的正确利巴韦林剂量和药物组合。
英文摘要
The treatment of chronic viral hepatitis with interferon is effective in only about 20% of such patients. Ribavirin can also lower abnormal liver tests in chronic hepatitis C. It is hoped that the combination of interferon and ribavirin therapy will improve the therapeutic potential of the individual drugs. This study will compare the elimination of a single dose of ribavirin in controls and patients with liver disease of varying severity thus permitting an assessment of the correct dose of ribavirin and of the drug combination in patients with chronic hepatitis C.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
海外基金